A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation

The development of specific antiviral compounds to SARS-CoV-2 is an urgent task. One of the obstacles for the antiviral development is the requirement of biocontainment because infectious SARS-CoV-2 must be handled in a biosafety level-3 laboratory. Replicon, a non-infectious self-replicative viral...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotaki, Tomohiro, Xie, Xuping, Shi, Pei-Yong, Kameoka, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838314/
https://www.ncbi.nlm.nih.gov/pubmed/33500537
http://dx.doi.org/10.1038/s41598-021-82055-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838314/
https://www.ncbi.nlm.nih.gov/pubmed/33500537
http://dx.doi.org/10.1038/s41598-021-82055-0

Ejemplares similares